CHIKV VLP vaccine

Phase 3Vaccine

BBavarian Nordic

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Chikungunya VirusRecruiting

Chikungunya VirusPhase 3

Recruiting

Timeline

Expected Milestones

Q3 2028

Phase 3Active, not recruiting

Long-Term Follow-up

NCT06007183

Q4 2028

Phase 3Recruiting

Immunogenicity

NCT07003984

Q2 2030

Phase 3Recruiting

Chikungunya Virus

NCT07467707

Clinical

Trials by Indication[1]

Immunogenicity2 trials

A Safety and Immunogenicity Study of CHIKV VLP Vaccine in Children.

Recruiting·BBavarian Nordic·Phase 3·NCT07003984·720 enrolled

Safety and Immunogenicity of CHIKV VLP Vaccine PXVX0317 in Adults ≥65 Years

Completed·BBavarian Nordic·Phase 3·NCT05349617·413 enrolled

Chikungunya Virus2 trials

A Study to Assess the Safety and Immunogenicity of PXVX0317 Chikungunya Virus Virus-Like Particle Vaccine

Completed·BBavarian Nordic·Phase 2·NCT05065983·25 enrolled

A Phase 3b Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of an Adjuvanted Chikungunya Virus Virus-like Particle (CHIKV VLP) Vaccine for the Prevention of Chikungunya Disease in Adolescents (12 to <18 Years) and Adults (≥18 Years)

Recruiting·BBavarian Nordic·Phase 3·NCT07467707·6,144 enrolled

Chikungunya2 trials

Trial of a Chikungunya Vaccine, PXVX0317 CHIKV-VLP, in Healthy Adults

Completed·BBavarian Nordic·Phase 2·NCT03483961·445 enrolled

A Phase 3 Trial of the VLP-Based Chikungunya Vaccine PXVX0317 (CHIKV VLP Vaccine)

Completed·BBavarian Nordic·Phase 3·NCT05072080·3,258 enrolled

Long-term Follow-up1 trial

Long-term Follow-up Study to Evaluate Safety and Immunogenicity of PXVX0317 Single or Booster Vaccination

Active, not recruiting·BBavarian Nordic·Phase 3·NCT06007183·800 enrolled

Sources

References

[1]
ClinicalTrials.gov — 7 trial records for CHIKV VLP vaccine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — CHIKV VLP vaccine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for CHIKV VLP vaccine. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Bavarian Nordic company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Vaccine[2]
Highest Phase: Phase 3[1]
Company: BBavarian Nordic